ThermoGenesis (THMO) 10-K 26 Mar 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Mar. 25, 2019	Jun. 29, 2018
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	0000811212
Trading Symbol	kool
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		22,149,147
Entity Public Float			$ 5,726
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 2,400,000	$ 3,513,000
Accounts receivable, net of allowance for doubtful accounts of $419,000 ($274,000 at December 31, 2017)	1,495,000	1,687,000
Accounts receivable – related party	14,000	862,000
Inventories, net of reserves of $258,000 ($1,069,000 at December 31, 2017)	4,493,000	4,798,000
Prepaid expenses and other current assets	224,000	594,000
Total current assets	8,626,000	11,454,000
Restricted cash	1,000,000	1,000,000
Equipment and leasehold improvements, net	2,562,000	2,996,000
Goodwill	781,000	13,976,000
Intangible assets, net	1,591,000	21,629,000
Other assets	51,000	56,000
Total assets	14,611,000	51,111,000
Current liabilities:
Accounts payable	2,423,000	2,079,000
Accrued payroll and related expenses	703,000	532,000
Deferred revenue	485,000	384,000
Related party payable		606,000
Interest payable – related party	1,513,000	657,000
Other current liabilities	1,241,000	1,206,000
Total current liabilities	6,365,000	5,464,000
Convertible promissory note – related party, less debt discount of $6,026,000 ($0 at December 31, 2017)	1,174,000	6,700,000
Derivative obligations	1,000	597,000
Noncurrent deferred tax liability		4,730,000
Other noncurrent liabilities	340,000	408,000
Total liabilities	7,880,000	17,899,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued and outstanding at December 31, 2018 and 2017
Common stock, $0.001 par value; 350,000,000 shares authorized; 21,649,147 issued and outstanding (10,872,428 at December 31,2017)	22,000	11,000
Paid in capital in excess of par	235,868,000	221,371,000
Accumulated deficit	(227,435,000)	(187,640,000)
Accumulated other comprehensive loss	(13,000)	(43,000)
Total Cesca Therapeutics Inc. stockholders’ equity	8,442,000	33,699,000
Non-controlling interests	(1,711,000)	(487,000)
Total equity	6,731,000	33,212,000
Total liabilities and stockholders’ equity	$ 14,611,000	$ 51,111,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accounts receivable, allowance for doubtful accounts	$ 419,000	$ 274,000
Inventories, reserves	258,000	1,069,000
Debt discount	$ 6,026,000	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	21,649,147	10,872,428
Common stock, shares outstanding (in shares)	21,649,147	10,872,428

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Net revenues	$ 4,334,000	$ 9,003,000	$ 14,217,000
Net revenues – related party	1,679,000	669,000	308,000
Total net revenues	6,013,000	9,672,000	14,525,000
Cost of revenues	3,858,000	7,479,000	8,686,000
Gross profit	2,155,000	2,193,000	5,839,000
Expenses:
Sales and marketing	935,000	1,359,000	1,531,000
Research and development	2,246,000	3,012,000	2,497,000
General and administrative	3,572,000	8,286,000	10,870,000
Impairment charges		33,081,000	310,000
Total operating expenses	6,753,000	45,738,000	15,208,000
Loss from operations	(4,598,000)	(43,545,000)	(9,369,000)
Other income (expense):
Interest expense	(541,000)	(2,697,000)	(20,519,000)
Fair value change of derivative instruments	133,000	596,000	(60,000)
Other income and (expenses)	(2,000)	(24,000)	180,000
Total other expense	(410,000)	(2,125,000)	(20,399,000)
Loss before benefit for income taxes	(5,008,000)	(45,670,000)	(29,768,000)
Benefit for income taxes	2,238,000	4,730,000	673,000
Net loss	(2,770,000)	(40,940,000)	(29,095,000)
Loss attributable to non-controlling interests	(487,000)	(1,224,000)
Net loss attributable to common stockholders	(2,283,000)	(39,716,000)	(29,095,000)
Other comprehensive loss:
Net loss	(2,770,000)	(40,940,000)	(29,095,000)
Foreign currency translation	(5,000)	30,000	(1,000)
Comprehensive loss	(2,775,000)	(40,910,000)	(29,096,000)
Comprehensive loss attributable to non-controlling interests	(487,000)	(1,224,000)
Comprehensive loss attributable to common stockholders	$ (2,288,000)	$ (39,686,000)	$ (29,096,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.23)	$ (2.16)	$ (3.27)
Weighted average common shares outstanding – Basic and diluted (in shares)	10,108,329	18,412,807	8,904,508

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Jun. 30, 2016	3,010,687
Balance at Jun. 30, 2016	$ 3,000	$ 188,569,000	$ (156,262,000)	$ (37,000)	$ 32,273,000		$ 32,273,000
Stock-based compensation expense, net of stock surrenders (in shares)	125,368
Stock-based compensation expense, net of stock surrenders		1,445,000			1,445,000		1,445,000
Shares issued upon debt conversion (in shares)	6,102,941
Shares issued upon debt conversion	$ 6,000	23,897,000			23,903,000		23,903,000
Issuance of common stock in financing, net of offering costs (in shares)	600,000
Issuance of common stock in financing, net of offering costs	$ 1,000	2,091,000			2,092,000		2,092,000
Common stock issued to directors in lieu of cash compensation (in shares)	5,463
Common stock issued to directors in lieu of cash compensation		16,000			16,000		16,000
Common stock issued to employees for prior year bonus (in shares)	71,409
Common stock issued to employees for prior year bonus		204,000			204,000		204,000
Foreign currency translation				(1,000)	(1,000)		(1,000)
Net loss			(29,095,000)		(29,095,000)		$ (29,095,000)
Exercise of stock options (in shares)							0
Balance (in shares) at Jun. 30, 2017	9,915,868
Balance at Jun. 30, 2017	$ 10,000	216,222,000	(185,357,000)	(38,000)	30,837,000		$ 30,837,000
Stock-based compensation expense, net of stock surrenders (in shares)	52,825
Stock-based compensation expense, net of stock surrenders		239,000			239,000		239,000
Issuance of common stock in financing, net of offering costs (in shares)	898,402
Issuance of common stock in financing, net of offering costs	$ 1,000	2,367,000			2,368,000		2,368,000
Foreign currency translation				(5,000)	(5,000)		(5,000)
Net loss			(2,283,000)		(2,283,000)	(487,000)	(2,770,000)
Fair value of subsidiary commonstock issued in acquisition		2,528,000			2,528,000		2,528,000
Exercise of stock options (in shares)	5,333
Exercise of stock options		15,000			15,000		15,000
Balance (in shares) at Dec. 31, 2017	10,872,428
Balance at Dec. 31, 2017	$ 11,000	221,371,000	(187,640,000)	(43,000)	33,699,000	(487,000)	33,212,000
Stock-based compensation expense, net of stock surrenders (in shares)	416
Stock-based compensation expense, net of stock surrenders		652,000			652,000		652,000
Issuance of common stock in financing, net of offering costs (in shares)	8,084,637
Issuance of common stock in financing, net of offering costs	$ 8,000	6,621,000			6,629,000		6,629,000
Foreign currency translation				30,000	30,000		30,000
Net loss			(39,716,000)		(39,716,000)	(1,224,000)	$ (40,940,000)
Exercise of stock options (in shares)							0
Exercise of warrants (in shares)	2,691,666
Exercise of warrants	$ 3,000	24,000			27,000		$ 27,000
Discount due to beneficial conversion features		7,200,000			7,200,000		7,200,000
Cumulative-effect adjustment from adoption of ASC 606 | Accounting Standards Update 2014-09 [Member]			(79,000)		(79,000)		(79,000)
Balance (in shares) at Dec. 31, 2018	21,649,147
Balance at Dec. 31, 2018	$ 22,000	$ 235,868,000	$ (227,435,000)	$ (13,000)	$ 8,442,000	$ (1,711,000)	$ 6,731,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (2,770,000)	$ (40,940,000)	$ (29,095,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	322,000	670,000	830,000
Stock-based compensation expense	291,000	652,000	1,461,000
(Recovery of) reserve for excess and slow-moving inventories	(162,000)	(11,000)	(203,000)
Bad debt expense	170,000	153,000	50,000
Amortization of debt discount		1,174,000	9,851,000
Amortization of debt issue costs			160,000
Change in fair value of derivative obligation	(133,000)	(596,000)	60,000
Deferred income tax benefit	2,238,000	4,730,000	673,000
Non-cash accrued interest			10,373,000
Loss on disposal of equipment and leasehold improvements	8,000	1,360,000	176,000
Impairment of intangible asset		33,081,000	310,000
Net changes in operating assets and liabilities:
Accounts receivable	987,000	1,045,000	(572,000)
Inventories	(367,000)	61,000	615,000
Prepaid expenses and other assets	(347,000)	370,000	24,000
Accounts payable	469,000	214,000	(1,062,000)
Related party payable		(606,000)	606,000
Accrued payroll and related expenses	148,000	172,000	(63,000)
Deferred revenue	(213,000)	24,000	(187,000)
Other current liabilities	481,000	922,000	26,000
Other noncurrent liabilities	37,000	2,000	98,000
Net cash (used in) operating activities	(3,317,000)	(6,983,000)	(7,215,000)
Cash flows from investing activities:
Cash paid for business acquisition	(1,000,000)
Capital expenditures	(296,000)	(1,238,000)	(375,000)
Net cash (used in) investing activities	(1,296,000)	(1,238,000)	(375,000)
Cash flows from financing activities:
Proceeds from convertible promissory note-related party	3,200,000	500,000	3,500,000
Payments on capital lease obligations	(29,000)	(45,000)	(84,000)
Proceeds from issuance of common stock and pre-funded warrants, net	2,368,000	6,629,000	2,092,000
Exercise of warrants		27,000
Exercise of options	15,000
Cash paid for taxes on vested stock	(52,000)		(134,000)
Net cash provided by financing activities	5,502,000	7,111,000	5,374,000
Effects of foreign currency rate changes on cash and cash equivalents	1,000	(3,000)	4,000
Net increase (decrease) in cash, cash equivalents and restricted cash	890,000	(1,113,000)	(2,212,000)
Cash, cash equivalents and restricted cash at beginning of period	3,623,000	4,513,000	5,835,000
Cash, cash equivalents and restricted cash at end of period	4,513,000	3,400,000	3,623,000
Supplemental disclosures of cash flow information:
Cash paid for interest	4,000	667,000	6,000
Supplemental non-cash financing and investing information:
Common stock issued for payment of convertible debenture and interest			23,903,000
Recording of beneficial conversion feature on debt		7,200,000
Transfer of inventories to equipment and leasehold improvements		420,000
Transfer of equipment to inventories		172,000	625,000
Acquisition of business:
Inventories	649,000
Equipment	585,000
Intangible assets	1,528,000
Goodwill	781,000
Liabilities assumed	15,000
Subsidiary common stock issued for acquisition of net assets	$ 2,528,000

Note 1 - Description of Busines

Note 1 - Description of Business, Going Concern and Basis of Presentation	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business , Going C oncern and Basis of Presentation Organization and Basis of Presentation Cesca Therapeutics Inc. (“Cesca Therapeutics,” “Cesca,” the “Company”), a Delaware corporation, develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company was founded in 1986 ® ® ® Cesca is an affiliate of the Boyalife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. In August 2017, June 30 December 31. 10 December 31, 2018 six December 31, 2017; June 30, 2017. July 1, 2016 June 30, 2017 2017”. Liquidity and Going Concern The Company has a Revolving Credit Agreement (the “Credit Agreement”) with Boyalife Asset Holding II, Inc. (Refer to Note 6 December 31, 2018, $7,200,000 $10,000,000 may may no On August 28, 2018, 1,000,000 $0.001 $0.18 2,965,000 $0.17 one $0.01 $684,000 $623,000 $61,000. December 31, 2018, none August 2018 February 26, 2019, On May 18, 2018, 6,475,001 2,691,666 $0.60 $5,500,000, $4,820,000 $680,000. one one one one one one one $0.60 five June 30, 2018, 2,691,666 May 2018 On March 28, 2018, 609,636 $2.27 $171,000, $1,213,000. 304,818 $2.68 six September 28, 2018, 5.5 At December 31, 2018, $2,400,000 $2,261,000. December 31, 2018 $227,435,000. one The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The consolidated financial statements do not may Principles of Consolidation The consolidated financial statements include the accounts of Cesca, its majority-owned subsidiary, ThermoGenesis, and its wholly-owned subsidiary, TotipotentRX Cell Therapy, Pvt. Ltd. “TotipotentRX”). During the year ended December 31, 2018, Non - controlling Interests The 20% not 80%

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) and pursuant to the rules and regulations of the United States Securities Exchange Commission (SEC) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Device Sales Device sales include devices and consumables for BioArchive, AXP, not Service Revenue Service revenue consists primarily of maintenance contracts for BioArchive, AXP and CAR-TXpress products. Devices sold have warranty periods of one two one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 December 31, 2018, $257,000 may The following table summarizes the revenues of the Company’s reportable segments for the year ended December 31, 2018: Year Ended December 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 4,131,000 $ 262,000 $ -- $ 4,393,000 BioArchive 1,792,000 1,306,000 -- 3,098,000 Manual Disposables 976,000 -- -- 976,000 CAR-TXpress 907,000 -- -- 907,000 Other -- -- 95,000 95,000 Total Device Segment 7,806,000 1,568,000 95,000 9,469,000 Clinical Development Segment: Bone Marrow -- 135,000 -- 135,000 Other 38,000 30,000 -- 68,000 Total Clinical Development 38,000 165,000 -- 203,000 Total $ 7,844,000 $ 1,733,000 $ 95,000 $ 9,672,000 There is no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not December 31, 2018 $384,000. $485,000 $384,000 December 31, 2018 2017, $303,000 $331,000 December 31, 2018 2017, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. 2019 2020 2021 2022 and beyond Total Service revenue $ 1,035,000 $ 369,000 $ 112,000 $ 1,516,000 Clinical revenue 14,000 14,000 14,000 $ 210,000 252,000 Total $ 1,049,000 $ 383,000 $ 126,000 $ 210,000 $ 1,768,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three may $11,000 $71,000 December 31, 2018 2017 not Foreign Currenc y Translation The Company’s reporting currency is the US dollar. The functional currency of the Company’s subsidiaries in India is the Indian rupee (INR). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not $30,000, 5,000 1,000 December 31, 2018, six December 31, 2017 June 30, 2017, Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not three ten not not For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not 350 ,”Intangibles-Goodwill and Other” not 50 Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Other observable inputs other than Level 1 not Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3 Accounts Receivable and Allowance for Doubtful Accounts The Company’s receivables are recorded when billed and represent claims against third may Inventories Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined on the first first not Because some of the Company’s products are highly dependent on government and third may may Equipment and Leasehold Improvements Equipment consisting of office furniture, computer, machinery and equipment is recorded at cost less accumulated depreciation. Repairs and maintenance costs are expensed as incurred. Depreciation for office furniture, computer, machinery and equipment is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight-line method over their estimated useful lives or the remaining lease period, whichever is shorter. When equipment and leasehold improvements is sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and the impact of any resulting gain or loss is recognized within general and administrative expenses in the consolidated statement of operations for the period. Warranty The Company provides for the estimated cost of product warranties at the time revenue is recognized. The Company’s warranty obligation is calculated based on estimated product failure rates, material usage and estimated service delivery costs incurred in correcting a product failure. Debt Discount and Issue Costs The Company amortizes debt discount and debt issue costs over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may first Stock - Based Compensation The Company has three 10. Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not not Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award’s vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that correspond to the expected term of the options. Expected Dividend – The Company has not not zero Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero Estimated Forfeitures – When estimating forfeitures, the Company considers voluntary and involuntary termination behavior as well as analysis of actual option forfeitures. Research and Development Research and development costs, consisting of salaries and benefits, costs of clinical trials, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory, scientific and clinical affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may no A cquired In-Process Research and Development Acquired in-process research and development (clinical protocols) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not first not not Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred. Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company’s customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary. Income Taxes The tax years 1999 2018 no no no The Company’s estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company’s assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company’s current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not one may Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company’s estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company’s pre-existing deferred tax assets. Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 2,965,000 December 31, 2018 December 31: December 31, December 31, June 30, 2018 2017 2017 Common stock equivalents of convertible promissory note and accrued interest 48,405,556 -- -- Vested Series A warrants 404,412 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 698,529 Warrants – other 16,162,267 3,725,782 3,725,782 Stock options 3,023,639 1,156,027 397,388 Restricted stock units -- 416 59,694 Total 68,694,403 5,985,166 5,285,805 ____________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not Recently Adopted Accounting Standards In July 2017, No. 2017 11, Earnings Per Share (Topic 260 480 815 - controlling Interests with a Scope Exception 2017 11 may no 2017 11 December 15, 2018, 2017 11 2017 11 April 1, 2018. April 1, 2018, not not April 16, 2018, 2017 11 6 Under Accounting Standard Codification (“ASC”) 815 40 35, 815 first 815, not On January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 “ASC606” not January 1, 2018. January 1, 2018 606, not 605 $79,000 January 1, 2018 606, 606 Recently Adopted Accounting Standards In January 2017, 2017 04 “Intangibles-Goodwill and Other (Topic 350 2 December 15, 2019. January 1, 2017. 2017 04 October 1, 2018. not Recently Issued Accounting Standards In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, not In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 718 December 15, 2018. not In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The adoption of the new standard is not January 1, 2019, The impact of adopting the new standard on retained earnings as of January 1, 2019

Note 3 - Acquisition of SynGen

Note 3 - Acquisition of SynGen	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Acquisition of SynGen On July 7, 2017, The business acquired in the Transaction excludes certain assets and liabilities of SynGen that ThermoGenesis did not The acquisition was accounted for under the acquisition method of accounting for business combinations which requires, among other things, that the assets acquired, and liabilities assumed be recognized at their fair values as of the acquisition date. Acquisition-related costs are not $208,000 six December 31, 2017 The consideration for the Transaction consisted of $1,000,000 2,000,000 20% $2,528,000. 2,000,000 Allocation of Consideration Transferred to Net Assets Acquired The following is the summary of the fair value of the assets acquired and the liabilities assumed by Cesca in the Transaction, reconciled to the consideration transferred. Purchase Price: Cash $ 1,000,000 2,000,000 common shares of ThermoGenesis 2,528,000 Fair value of assets acquired: Inventories 649,000 Developed technology 318,000 Trade name 26,000 In process technology 1,143,000 Customer relationships 41,000 Total intangible assets 1,528,000 Equipment 585,000 Total assets 2,762,000 Fair value of liabilities assumed: Other liabilities 15,000 Net assets acquired (2,747,000 ) Goodwill $ 781,000 Supplemental Pro Forma Data The Company used the acquisition method of accounting to account for the SynGen acquisition and, accordingly, the results of SynGen are included in the Company’s consolidated financial statements for the period subsequent to the date of acquisition. For the year ended December 31, 2018 six December 31, 2017 $907,000 $107,000, July 7, 2017, no six December 31, 2017 June 30, 2017 July 1, 2016. Six Months Ended December 31 Year Ended June 30 2017 2017 Net revenues $ 6,013,000 $ 15,592,000 Net loss $ (2,600,000 ) $ (30,701,000 ) Basic and diluted net loss per common share $ (0.21 ) $ (3.39 ) The unaudited pro forma financial information reflects certain adjustments related to the acquisition, such as the incremental amortization expense in connection with recording acquired identifiable intangible assets at fair value, the revised payroll expense associated with the new salaries of SynGen employees resulting from the merger, the elimination of SynGen expenses related to debt issuance costs, interest and other warrant related expenses, the elimination of the legal fees paid by both parties related to the litigation between Cesca and SynGen as ceasing the litigation was part of the Asset Acquisition Agreement and costs directly related to the acquisition.

Note 4 - Intangible Assets and

Note 4 - Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	4 . Intangible Asset s and Goodwill During the year ended December 31, 2018, June 30, 2018 3 The Company recorded an impairment charge of $13,195,000 $19,886,000 December 31, 2018, Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (current year) (152,000 ) -- Impairment loss (19,886,000 ) (13,195,000 ) Balance at December 31, 2018, net $ 1,591,000 $ 781,000 Also, there was a $310,000 not June 30, 2017 Intangible assets consist of the following based on the Company’s determination of the fair value of identifiable assets acquired: As of December 31, 2018 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 54,000 $ 38,000 $ 16,000 Developed technology 10 318,000 48,000 270,000 Licenses 7 448,000 307,000 141,000 Device registration 7 84,000 68,000 $ 16,000 -- Customer relationships 3 451,000 430,000 -- 21,000 Amortizable intangible assets 1,355,000 891,000 16,000 448,000 In process technology 1,143,000 -- -- 1,143,000 Clinical protocols 19,870,000 -- 19,870,000 -- Total $ 22,368,000 $ 891,000 $ 19,886,000 $ 1,591,000 As of December 31, 2017 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Net Trade names 7 $ 56,000 $ 21,000 $ 35,000 Developed technology 10 318,000 16,000 302,000 Licenses 7 489,000 271,000 218,000 Customer relationships 3 490,000 456,000 34,000 Device registration 7 92,000 65,000 27,000 Amortizable intangible assets 1,445,000 829,000 616,000 In process technology 1,143,000 -- 1,143,000 Clinical protocols 19,870,000 -- 19,870,000 Total $ 22,458,000 $ 829,000 $ 21,629,000 The change in the gross carrying amount is due to foreign currency exchange fluctuations and the write-off of assets for impairment. Amortization of intangible assets was $131,000 December 31, 2018; $68,000 six December 31, 2017 $359,000 June 30, 2017. not not not not December 31, 2018. Year Ended December 31, 2019 $ 122,000 2020 111,000 2021 40,000 2022 32,000 2023 32,000 Thereafter 111,000 Total $ 448,000

Note 5 - Equipment, Net

Note 5 - Equipment, Net	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Equipment and Leasehold Improvements, Net Equipment and leasehold improvements consisted of the following: December 31, December 31, 2018 2017 Estimated Useful Life (years) Machinery and equipment $ 6,136,000 $ 6,507,000 2.5 - 10 Computer and software 664,000 718,000 2 - 5 Office equipment 264,000 253,000 5 - 10 Leasehold improvements 931,000 528,000 Shorter of 5 years or remaining lease term Total equipment 7,995,000 8,006,000 Less accumulated depreciation and amortization (5,433,000 ) (5,010,000 ) Total equipment and leasehold improvements, net $ 2,562,000 $ 2,996,000 Depreciation and amortization expense for the year ended December 31, 2018 $539,000, six December 31, 2017 $254,000 June 30, 2017 $408,000.

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6 . Related Party Transactions Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( $7,200,000 $6,700,000 December 31, 2018 2017, $2,800,000 may may no The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five December 31, 2018 not not December 31, 2018. The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no The Credit Agreement and Note were amended on April 16, 2018. ● The Lender was granted the right to convert, at any time, outstanding principal and accrued but unpaid interest under the Credit Agreement into shares of Common Stock at a conversion price equal to $1.61 90% 10 April 2018 ● If the Company after April 16, 2018 ● The Company has been granted the right to defer payment of the $657,000 December 31, 2017 December 31, 2018, $5.0 $657,000 May 2018. On May 7, 2018, No. 1 On May 18, 2018, $0.60 $1.61 $0.60. August 28, 2018, $0.18 $0.60 $0.18. The Company accounted for the Amended Credit Agreement as a loan modification. As discussed in Note 2, 2017 11 Accounting for Certain Financial Instruments with Down Round Features”. 2017 11 not not $7,200,000. $1,174,000 December 31, 2018. The Company recorded interest expense of $1,513,000 December 31, 2018, $535,000 six December 31, 2017 $122,000 June 30, 2017 $1,513,000 $657,000 December 31, 2018 2017, Distributo r Agreement On August 21, 2017, The term of the agreement is for three two Revenues During the year ended December 31, 2018, $665,000 $0 December 31, 2018. six December 31, 2017, $1,679,000 $862,000 December 31, 2017. June 30, 2017, $308,000 License Agreement On March 12, 2018, X Pursuant to the terms of the Agreement, ThermoGenesis has granted IncoCell an exclusive license to purchase and use, at a discounted purchase price, X ten may ninety 90 December 31, 2018, $14,000 $14,000 December 31, 2018. Bill Payment Arrangement The Company entered into a bill payment arrangement whereby Boyalife Group Ltd. (Payor), the Company’s largest shareholder, agreed to pay the Company’s legal expenses payable to the Company’s attorney related to certain litigation involving SynGen (the “Bill Payment Arrangement”), although the Company remains jointly and severally liable for the payment of such legal fees. The terms of the Bill Payment Arrangement provided that the Company will reimburse Payor for any and all amounts paid by Payor in connection with the Bill Payment Arrangement under certain specified events. There is no $606,000 December 31, 2017. $606,000 May 2018.

Note 7 - Convertible Debentures

Note 7 - Convertible Debentures	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	7 . Convertible Debentures February 2016 In February 2016 $15,000,000 735,294 $3.40 $2,500,000 $12,500,000 3,676,471 3,529,412 $8.00 five 80% August 13, 2016 December 31, 2018. On August 22, 2016, $12,500,000 $8,250,000 6,102,941 The 2,426,470 $11,403,000 August 22, 2016. $3,153,000 $9,538,000 $155,000

Note 8 - Derivative Obligations

Note 8 - Derivative Obligations	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	8. Derivative Obligations Series A Warrants Series A warrants to purchase 404,412 June 30, 2016. December 31, 2018 December 31, 2017 June 30, Market price of common stock $0.27 $3.00 $3.17 Expected volatility 94% 107% 110% Contractual term (years) 2.2 3.2 3.7 Discount rate 2.48% 1.99% 1.66% Dividend rate 0% 0% 0% Exercise price $8.00 $8.00 $8.00 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded a gain (loss) of $596,000 December 31, 2018, $133,000 six December 31, 2017 $60,000 June 30, 2017, The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of December 31, 2018 2017: Derivative Obligation December 31, 2018 December 31, 2017 Balance $1,000 $597,000 Level 1 $- $- Level 2 $- $- Level 3 $1,000 $597,000 The following table reflects the change in fair value of the Company’s derivative: Amount Balance – June 30, 2017 $ 730,000 Change in fair value of derivative obligation (133,000 ) Balance – December 31, 2017 597,000 Change in fair value of derivative obligation (596,000 ) Balance – December 31, 2018 $ 1,000

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9 . Commitments and Contingencies Operating Leases The Company leases the Rancho Cordova, California and Gurgaon, India facilities pursuant to operating leases. The Rancho Cordova lease expires in May 2019 January 2019 five September 2023; September 2019 three 2019 $ 311,000 2020 301,000 2021 310,000 2022 319,000 2023 329,000 Thereafter 139,000 Total $ 1,709,000 Rent expense was $517,000 December 31, 2018. $241,000 six December 31, 2017 $291,000 June 30, 2017. Financial Covenants Effective May 15, 2017, one not $2,000,000. December 31, 2018 February 28, 2019. Potential Severance Payments The Company’s Chief Executive Officer (CEO) has rights upon termination under his employment agreement. With respect to his agreement at December 31, 2018, $2.3 Contingencies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 August 2016. October 2017, $1,000,000 June 26, 2018. September 24, 2018, No no December 31, 2018. In the normal course of operations, the Company may December 31, 2018, may not Warranty The Company offers a warranty on all of the Company’s non-disposable products of one two Changes in the Company’s product liability which is included in other current liabilities during the period are as follows: Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 Beginning balance $ 291,000 $ 588,000 $ 566,000 Warranties issued during the period 199,000 95,000 120,000 Settlements made during the period (252,000 ) (359,000 ) (93,000 ) Changes in liability for pre-existing warranties during the period (52,000 ) (33,000 ) (5,000 ) Ending balance $ 186,000 $ 291,000 $ 588,000

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10 . Stockholders ’ Equity Common Stock On August 28, 2018, 1,000,000 $0.18 2,965,000 $0.17 one $0.01 $684,000 $623,000 $61,000. December 31, 2018, none August 2018 February 26, 2019, On May 18, 2018, 6,475,001 2,691,666 $0.60 $5,500,000, $4,820,000 $680,000. one one one one one one one $0.60 five 2,691,666 May 2018 second 2018. On March 28, 2018, 609,636 $2.27 $171,000, $1,213,000. 304,818 $2.68 six September 28, 2018, 5.5 On December 1, 2017, 898,402 $3.00 $2.7 $327,000, $2,368,000. On August 22, 2016, $12,500,000 $8,250,000 6,102,941 On August 3, 2016, 600,000 $4.10 $369,000, $2,092,000. In July 2016, 118,288 2016 46,879 Warrants A summary of warrant activity is as follows: Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted- Average Exercise Price Per Share Beginning balance 4,828,723 $ 9.37 4,828,723 $ 9.37 4,828,723 $ 9.37 Warrants granted 15,128,151 $ 0.42 -- -- Warrants exercised (2,691,666 ) $ 0.01 Warrants expired/canceled -- -- -- Outstanding 17,265,208 $ 2.99 4,828,723 $ 9.37 4,828,723 $ 9.37 Exercisable 16,566,679 $ 2.78 4,130,194 $ 9.60 4,130,194 $ 9.60 Equity Plans and Agreements The Company recorded stock-based compensation of $652,000 December 31, 2018, $291,000 six December 31, 2017 $1,461,000 June 30, 2017. The Amended 2016 2016 May 2017, 600,000 may June 22, 2018, 2016 may 1,325,000 December 14, 2018, 2016 may 1,325,000 3,950,000 not December 14, 2019. December 31, 2018, 901,100 2016 The 2012 2012 25,000 2012 100% not ten one December 31, 2018, 2,444 The 2006 2006 2006 not 2016. December 31, 2018, 62,676 On December 29, 2017, 2017 280,000 December 29, 2017. 1,000,000 775,000 December 31, 2018. On December 14, 2018, 2,140,000 $0.2979 five first four 1,699,333 2016 December 14, 2019. not On December 29, 2017, 300,000 $3.00 five December 31, 2018, 2019, 2020, 2021 2022. On July 7, 2016, may $276,000. 104,000 2006 July 26, 2016, 98,417 $266,000 July 1, 2017, July 1, 2017 eight June 30, 2017, 51,636 46,781 July 1, 2017. Upon the termination of the employment of the Company’s CEO in November 2016 March 2017, $539,000 December 31, 2016, 72,496 79,720 $94,000 March 31, 2017 16,248 15,914 90 no Stock Options The Company issues new shares of common stock upon exercise of stock options. The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at January 1, 2018 1,156,027 $ 3.92 Granted 2,233,500 $ 0.40 Forfeited/cancelled (338,518 ) $ 3.10 Expired (27,370 ) $ 4.83 Exercised -- Outstanding at December 31, 2018 3,023,639 $ 1.40 9.3 -- Vested and Expected to Vest at December 31, 2018 1,893,518 $ 1.77 8.9 -- Exercisable at December 31, 2018 901,742 $ 2.79 8.1 -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no December 31, 2018 June 30, 2017. six December 31, 2017, $8,000 On July 7, 2016, 156,100 2016 $2.86, six three seven Non-vested stock option activity for the year ended December 31, 2018, Non-vested Stock Options Weighted-Average Grant Date Fair Value Outstanding at January 1, 2018 835,708 $2.37 Granted 2,233,500 $0.32 Vested (651,180 ) $0.97 Forfeited (296,131 ) $2.35 Outstanding at December 31, 2018 2,121,897 $0.64 The fair value of the Company’s stock options granted for the year ended December 31, 2018, six December 31, 2017 June 30, 2017 Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 Expected life (years) 6 6 4 Risk-free interest rate 2.7% 2.3% 1.3% Expected volatility 103% 95% 102% Dividend yield 0% 0% 0% The weighted average grant date fair value of options granted during the year ended December 31, 2018, six December 31, 2017 June 30, 2017 $0.32, $2.36 $2.16, At December 31, 2018, not $1,202,000. four December 31, 2018, six December 31, 2017 June 30, 2017 $633,000, $209,000 $572,000, Common Stock Restricted Awards The following is a summary of restricted stock unit activity: Year Ended December 31, Six Month Ended December 31, Year Ended June 30, 2018 2017 2017 Number of Shares Weighted -Average Grant Date Fair Value Number of Shares Weighted -Average Grant Date Fair Value Number of Shares Weighted -Average Grant Date Fair Value Balance at beginning of period 416 $17.60 59,694 $4.62 63,566 $14.96 Granted -- 10,000 $3.26 123,417 $4.55 Vested (416 ) $17.60 (69,278 ) $4.35 (125,513 ) $9.47 Forfeited -- -- (1,776 ) $27.05 Outstanding at end of period -- 416 $17.60 59,694 $4.62 In connection with the vesting of the restricted stock unit awards, the election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld 16,456 six December 31, 2017 145 June 30, 2017,

Note 11 - Concentrations

Note 11 - Concentrations	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	11 . Concentrations A customer had an accounts receivable balance of $494,000 33% $172,000 7% December 31, 2018 2017, $229,000 15% $12,000 December 31, 2018 2017, second $220,000 15% $464,000 18% December 31, 2018 2017, $0 $862,000 34% December 31, 2018 2017, Revenues from a customer totaled $2,120,000 22%, $560,000 9% $3,263,000 22% December 31, 2018, six December 31, 2017 June 30, 2017, one $861,000 9%, $520,000 9% $1,048,000 7% December 31, 2018, six December 31, 2017 June 30, 2017, $664,000 7%, $1,679,000 28% $308,000 2% December 31, 2018, six December 31, 2017 June 30, 2017, second $461,000 5%, $480,000 8% $2,842,000 20% December 31, 2018, six December 31, 2017 June 30, 2017, not August 2017 The following represents the Company’s revenues by product platform for the: Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 AXP $ 4,393,000 $ 2,475,000 $ 8,715,000 BioArchive 3,098,000 2,642,000 3,318,000 Manual Disposables 976,000 476,000 1,195,000 CAR-TXpress 907,000 151,000 Bone Marrow 135,000 180,000 745,000 Other 163,000 89,000 552,000 $ 9,672,000 $ 6,013,000 $ 14,525,000 The Company had sales in the following geographical areas for the: Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 2018 United States $ 4,854,000 $ 1,970,000 $ 6,675,000 Asia – other 1,717,000 983,000 1,951,000 Europe 1,165,000 721,000 1,739,000 China 1,143,000 2,176,000 3,296,000 Other 793,000 163,000 864,000 $ 9,672,000 $ 6,013,000 $ 14,525,000 The Company attributes revenue to different geographic areas based on where items are shipped or services are performed. Two suppliers accounted for 43% 14% December 31, 2018. 61% six December 31, 2017. 64% 20% June 30, 2017. The Company has a contract manufacturer in Costa Rica that produces certain disposables. The Company’s equipment and leasehold improvements, net of accumulated depreciation, is summarized below by geographic area: December 31, December 31, 2018 2017 United States $ 1,614,000 $ 2,265,000 Costa Rica 601,000 276,000 India 211,000 288,000 All other countries 136,000 167,000 Total equipment, net $ 2,562,000 $ 2,996,000

Note 12 - Segment Reporting

Note 12 - Segment Reporting	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	12 . Segment Reporting The Company has two The Clinical Development Segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. The Device Segment is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The following table summarizes the operating results of the Company’s reportable segments: Year Ended December 31, 2018 Clinical Development Device Total Net revenues $ 202,000 $ 9,470,000 $ 9,672,000 Cost of revenues 274,000 7,205,000 7,479,000 Gross profit (72,000 ) 2,265,000 2,193,000 Operating expenses 37,340,000 8,398,000 45,738,000 Operating loss $ (37,412,000 ) $ (6,133,000 ) $ (43,545,000 ) Depreciation and amortization $ 272,000 $ 398,000 $ 670,000 Stock-based compensation expense $ 473,000 $ 179,000 $ 652,000 Goodwill -- $ 781,000 $ 781,000 Total assets $ 3,796,000 $ 10,815,000 $ 14,611,000 Six Months Ended December 31, 2017 Clinical Development Device Total Net revenues $ 186,000 $ 5,827,000 $ 6,013,000 Cost of revenues 205,000 3,653,000 3,858,000 Gross profit (19,000 ) 2,174,000 2,155,000 Operating expenses 2,138,000 4,615,000 6,753,000 Operating loss $ (2,157,000 ) $ (2,441,000 ) $ (4,598,000 ) Depreciation and amortization $ 152,000 $ 170,000 $ 322,000 Stock-based compensation expense $ 164,000 $ 127,000 $ 291,000 Goodwill $ 13,195,000 $ 781,000 $ 13,976,000 Total assets $ 41,261,000 $ 9,850,000 $ 51,111,000 Year Ended June 30, 2017 Clinical Development Device Total Net revenues $ 492,000 $ 14,033,000 $ 14,525,000 Cost of revenues 466,000 8,220,000 8,686,000 Gross profit 26,000 5,813,000 5,839,000 Operating expenses 9,095,000 6,113,000 15,208,000 Operating loss $ (9,069,000 ) $ (300,000 ) $ (9,369,000 ) Depreciation and amortization $ 501,000 $ 329,000 $ 830,000 Stock-based compensation expense $ 970,000 $ 491,000 $ 1,461,000

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13 . Income Taxes Loss before income tax benefits was comprised of $45,458,000 $212,000 December 31, 2018, $4,551,000 $457,000 six December 31, 2017 $29,005,000 $763,000 June 30, 2017. The reconciliation of federal income tax attributable to operations computed at the federal statutory tax rate to income tax benefit is as follows for the: Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 Statutory federal income tax benefit $ (9,591,000 ) $ (1,703,000 ) $ (10,121,000 ) Intangible assets 3,119,000 -- -- Change in valuation allowance (2,084,000 ) -- -- Expiration of net operating losses 1,271,000 (14,427,000 ) 2,281,000 United States tax reform rate change -- 13,658,000 -- Disallowed financing costs 240,000 149,000 6,959,000 State and local taxes 2,344,000 60,000 88,000 Other (29,000 ) 25,000 120,000 Total income tax benefit $ (4,730,000 ) $ (2,238,000 ) $ (673,000 ) The income tax benefit for the year ended December 31, 2018 $4,730,000 no The deferred income tax benefit for the six December 31, 2017 $2,238,000 December 22, 2017. 21% 35% 14%. December 22, 2017, $13,658,000 no 21% The deferred income tax benefit of $673,000 June 30, 2017 $559,000 2017, $157,000 2016 $402,000 2016. June 30, 2015 June 30, 2016, 2017. not not At December 31, 2018, $125,578,000 $37,520,000, 2019 2038. December 31, 2018 $2,430,000 2019 2026. At December 31, 2018, $1,604,000 2019 2038, $1,475,000 not Significant components of the Company’s deferred tax assets and liabilities for federal and state income taxes are as follows: December 31, December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 27,312,000 $ 29,682,000 Income tax credit carryforwards 2,769,000 2,667,000 Stock compensation 850,000 751,000 Other 1,027,000 831,000 Total deferred tax assets 31,958,000 33,931,000 Deferred tax liabilities Indefinite lived intangible assets -- (4,730,000 ) Depreciation and amortization (419,000 ) (126,000 ) Total deferred tax liabilities (419,000 ) (4,856,000 ) Valuation allowance (31,539,000 ) (33,805,000 ) Net deferred taxes $ -- $ (4,730,000 ) ASC 740 not." not The valuation allowance decreased by ( $2,266,000 December 31, 2018, $14,296,000 six December 31, 2017 $2,209,000 June 30, 2017. The transition tax is based on total post- 1986 December 31, 2018, not no not not In August 2016, 1986. may December 31, 2018,

Note 14 - Employee Retirement P

Note 14 - Employee Retirement Plan	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	14 . Employee Retirement Plan The Company sponsors an Employee Retirement Plan, generally available to all employees, in accordance with Section 401 may may no December 31, 2018, six December 31, 2017 June 30, 2017.

Note 15 - Prior Period Financia

Note 15 - Prior Period Financial Statement Revision	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounting Changes and Error Corrections [Text Block]	15. Prior Period Financial Statement Revision During the first 2019, six December 31, 2017. No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, codified in Accounting Standards Codification (ASC) 250 10 20, not six December 31, 2017. The effect of the correction of the immaterial error on the Company’s statement of comprehensive loss was as follows: For the Six Months Ended December 31, 2017 Statement of Comprehensive Loss Amounts Previously Reported Adjustment As Revised Net loss $ (2,283,000 ) $ (487,000 ) $ (2,770,000 ) Other comprehensive loss: Foreign currency translation adjustments (5,000 ) -- (5,000 ) Comprehensive loss (2,288,000 ) (487,000 ) (2,775,000 ) Comprehensive loss attributable to non-controlling interests (487,000 ) -- (487,000 ) Comprehensive loss attributable to common stockholders $ (1,801,000 ) $ (487,000 ) $ (2,288,000 )

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	1 6 . Subsequent Events The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that no On January 1, 2019, July 2017 20% 20% 80% 100% On January 29, 2019, $800,000 six $0.001 $0.18 2 90% $0.05 The Notes bear interest at the rate of twenty-four 24% eighteen 18 not fourteen may On the date that is six may 4.99% 9.99%

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) and pursuant to the rules and regulations of the United States Securities Exchange Commission (SEC) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: Step 1 Step 2 not Step 3 Step 4 one Step 5 Device Sales Device sales include devices and consumables for BioArchive, AXP, not Service Revenue Service revenue consists primarily of maintenance contracts for BioArchive, AXP and CAR-TXpress products. Devices sold have warranty periods of one two one three not Clinical Services Service revenue in our Clinical Development Segment includes point of care procedures and cord blood processing and storage. Point of care procedures are recognized when the procedures are performed. Cord blood processing and storage is recognized as the performance obligations are satisfied. Processing revenue is recognized when that performance obligation is completed immediately after the baby’s birth, with storage revenue recorded as deferred revenue and recognized ratably over time for up to 21 December 31, 2018, $257,000 may The following table summarizes the revenues of the Company’s reportable segments for the year ended December 31, 2018: Year Ended December 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 4,131,000 $ 262,000 $ -- $ 4,393,000 BioArchive 1,792,000 1,306,000 -- 3,098,000 Manual Disposables 976,000 -- -- 976,000 CAR-TXpress 907,000 -- -- 907,000 Other -- -- 95,000 95,000 Total Device Segment 7,806,000 1,568,000 95,000 9,469,000 Clinical Development Segment: Bone Marrow -- 135,000 -- 135,000 Other 38,000 30,000 -- 68,000 Total Clinical Development 38,000 165,000 -- 203,000 Total $ 7,844,000 $ 1,733,000 $ 95,000 $ 9,672,000 There is no no not may not Payments from domestic customers are normally due in two may 120 no Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not December 31, 2018 $384,000. $485,000 $384,000 December 31, 2018 2017, $303,000 $331,000 December 31, 2018 2017, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. 2019 2020 2021 2022 and beyond Total Service revenue $ 1,035,000 $ 369,000 $ 112,000 $ 1,516,000 Clinical revenue 14,000 14,000 14,000 $ 210,000 252,000 Total $ 1,049,000 $ 383,000 $ 126,000 $ 210,000 $ 1,768,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three may $11,000 $71,000 December 31, 2018 2017 not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currenc y Translation The Company’s reporting currency is the US dollar. The functional currency of the Company’s subsidiaries in India is the Indian rupee (INR). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not $30,000, 5,000 1,000 December 31, 2018, six December 31, 2017 June 30, 2017,
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not three ten not not For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not 350 ,”Intangibles-Goodwill and Other” not 50
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Other observable inputs other than Level 1 not Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3
Receivables, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts The Company’s receivables are recorded when billed and represent claims against third may
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined on the first first not Because some of the Company’s products are highly dependent on government and third may may
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment and Leasehold Improvements Equipment consisting of office furniture, computer, machinery and equipment is recorded at cost less accumulated depreciation. Repairs and maintenance costs are expensed as incurred. Depreciation for office furniture, computer, machinery and equipment is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight-line method over their estimated useful lives or the remaining lease period, whichever is shorter. When equipment and leasehold improvements is sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and the impact of any resulting gain or loss is recognized within general and administrative expenses in the consolidated statement of operations for the period.
Standard Product Warranty, Policy [Policy Text Block]	Warranty The Company provides for the estimated cost of product warranties at the time revenue is recognized. The Company’s warranty obligation is calculated based on estimated product failure rates, material usage and estimated service delivery costs incurred in correcting a product failure.
Debt, Policy [Policy Text Block]	Debt Discount and Issue Costs The Company amortizes debt discount and debt issue costs over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method.
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may first
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock - Based Compensation The Company has three 10. Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not not Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award’s vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that correspond to the expected term of the options. Expected Dividend – The Company has not not zero Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero Estimated Forfeitures – When estimating forfeitures, the Company considers voluntary and involuntary termination behavior as well as analysis of actual option forfeitures.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs, consisting of salaries and benefits, costs of clinical trials, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory, scientific and clinical affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may no
Business Combinations Policy [Policy Text Block]	A cquired In-Process Research and Development Acquired in-process research and development (clinical protocols) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not first not not
Legal Costs, Policy [Policy Text Block]	Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company’s customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Clinical Development Segment, is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis subsidiary.
Income Tax, Policy [Policy Text Block]	Income Taxes The tax years 1999 2018 no no no The Company’s estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company’s assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company’s current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not one may Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company’s estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company’s pre-existing deferred tax assets.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 2,965,000 December 31, 2018 December 31: December 31, December 31, June 30, 2018 2017 2017 Common stock equivalents of convertible promissory note and accrued interest 48,405,556 -- -- Vested Series A warrants 404,412 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 698,529 Warrants – other 16,162,267 3,725,782 3,725,782 Stock options 3,023,639 1,156,027 397,388 Restricted stock units -- 416 59,694 Total 68,694,403 5,985,166 5,285,805 ____________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In July 2017, No. 2017 11, Earnings Per Share (Topic 260 480 815 - controlling Interests with a Scope Exception 2017 11 may no 2017 11 December 15, 2018, 2017 11 2017 11 April 1, 2018. April 1, 2018, not not April 16, 2018, 2017 11 6 Under Accounting Standard Codification (“ASC”) 815 40 35, 815 first 815, not On January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 “ASC606” not January 1, 2018. January 1, 2018 606, not 605 $79,000 January 1, 2018 606, 606 Recently Adopted Accounting Standards In January 2017, 2017 04 “Intangibles-Goodwill and Other (Topic 350 2 December 15, 2019. January 1, 2017. 2017 04 October 1, 2018. not Recently Issued Accounting Standards In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, not In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 718 December 15, 2018. not In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The adoption of the new standard is not January 1, 2019, The impact of adopting the new standard on retained earnings as of January 1, 2019

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 4,131,000 $ 262,000 $ -- $ 4,393,000 BioArchive 1,792,000 1,306,000 -- 3,098,000 Manual Disposables 976,000 -- -- 976,000 CAR-TXpress 907,000 -- -- 907,000 Other -- -- 95,000 95,000 Total Device Segment 7,806,000 1,568,000 95,000 9,469,000 Clinical Development Segment: Bone Marrow -- 135,000 -- 135,000 Other 38,000 30,000 -- 68,000 Total Clinical Development 38,000 165,000 -- 203,000 Total $ 7,844,000 $ 1,733,000 $ 95,000 $ 9,672,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	2019 2020 2021 2022 and beyond Total Service revenue $ 1,035,000 $ 369,000 $ 112,000 $ 1,516,000 Clinical revenue 14,000 14,000 14,000 $ 210,000 252,000 Total $ 1,049,000 $ 383,000 $ 126,000 $ 210,000 $ 1,768,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, December 31, June 30, 2018 2017 2017 Common stock equivalents of convertible promissory note and accrued interest 48,405,556 -- -- Vested Series A warrants 404,412 404,412 404,412 Unvested Series A warrants (1) 698,529 698,529 698,529 Warrants – other 16,162,267 3,725,782 3,725,782 Stock options 3,023,639 1,156,027 397,388 Restricted stock units -- 416 59,694 Total 68,694,403 5,985,166 5,285,805

Note 3 - Acquisition of SynGen

Note 3 - Acquisition of SynGen (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Purchase Price: Cash $ 1,000,000 2,000,000 common shares of ThermoGenesis 2,528,000 Fair value of assets acquired: Inventories 649,000 Developed technology 318,000 Trade name 26,000 In process technology 1,143,000 Customer relationships 41,000 Total intangible assets 1,528,000 Equipment 585,000 Total assets 2,762,000 Fair value of liabilities assumed: Other liabilities 15,000 Net assets acquired (2,747,000 ) Goodwill $ 781,000
Business Acquisition, Pro Forma Information [Table Text Block]	Six Months Ended December 31 Year Ended June 30 2017 2017 Net revenues $ 6,013,000 $ 15,592,000 Net loss $ (2,600,000 ) $ (30,701,000 ) Basic and diluted net loss per common share $ (0.21 ) $ (3.39 )

Note 4 - Intangible Assets an_2

Note 4 - Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	Intangible Assets Goodwill Balance at December 31, 2017, net $ 21,629,000 $ 13,976,000 Amortization and foreign exchange (current year) (152,000 ) -- Impairment loss (19,886,000 ) (13,195,000 ) Balance at December 31, 2018, net $ 1,591,000 $ 781,000
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of December 31, 2018 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Impairment Net Trade names 3 $ 54,000 $ 38,000 $ 16,000 Developed technology 10 318,000 48,000 270,000 Licenses 7 448,000 307,000 141,000 Device registration 7 84,000 68,000 $ 16,000 -- Customer relationships 3 451,000 430,000 -- 21,000 Amortizable intangible assets 1,355,000 891,000 16,000 448,000 In process technology 1,143,000 -- -- 1,143,000 Clinical protocols 19,870,000 -- 19,870,000 -- Total $ 22,368,000 $ 891,000 $ 19,886,000 $ 1,591,000 As of December 31, 2017 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Net Trade names 7 $ 56,000 $ 21,000 $ 35,000 Developed technology 10 318,000 16,000 302,000 Licenses 7 489,000 271,000 218,000 Customer relationships 3 490,000 456,000 34,000 Device registration 7 92,000 65,000 27,000 Amortizable intangible assets 1,445,000 829,000 616,000 In process technology 1,143,000 -- 1,143,000 Clinical protocols 19,870,000 -- 19,870,000 Total $ 22,458,000 $ 829,000 $ 21,629,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ended December 31, 2019 $ 122,000 2020 111,000 2021 40,000 2022 32,000 2023 32,000 Thereafter 111,000 Total $ 448,000

Note 5 - Equipment, Net (Tables

Note 5 - Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, December 31, 2018 2017 Estimated Useful Life (years) Machinery and equipment $ 6,136,000 $ 6,507,000 2.5 - 10 Computer and software 664,000 718,000 2 - 5 Office equipment 264,000 253,000 5 - 10 Leasehold improvements 931,000 528,000 Shorter of 5 years or remaining lease term Total equipment 7,995,000 8,006,000 Less accumulated depreciation and amortization (5,433,000 ) (5,010,000 ) Total equipment and leasehold improvements, net $ 2,562,000 $ 2,996,000

Note 8 - Derivative Obligatio_2

Note 8 - Derivative Obligations (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	December 31, 2018 December 31, 2017 June 30, Market price of common stock $0.27 $3.00 $3.17 Expected volatility 94% 107% 110% Contractual term (years) 2.2 3.2 3.7 Discount rate 2.48% 1.99% 1.66% Dividend rate 0% 0% 0% Exercise price $8.00 $8.00 $8.00
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Derivative Obligation December 31, 2018 December 31, 2017 Balance $1,000 $597,000 Level 1 $- $- Level 2 $- $- Level 3 $1,000 $597,000
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – June 30, 2017 $ 730,000 Change in fair value of derivative obligation (133,000 ) Balance – December 31, 2017 597,000 Change in fair value of derivative obligation (596,000 ) Balance – December 31, 2018 $ 1,000

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2019 $ 311,000 2020 301,000 2021 310,000 2022 319,000 2023 329,000 Thereafter 139,000 Total $ 1,709,000
Schedule of Product Warranty Liability [Table Text Block]	Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 Beginning balance $ 291,000 $ 588,000 $ 566,000 Warranties issued during the period 199,000 95,000 120,000 Settlements made during the period (252,000 ) (359,000 ) (93,000 ) Changes in liability for pre-existing warranties during the period (52,000 ) (33,000 ) (5,000 ) Ending balance $ 186,000 $ 291,000 $ 588,000

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted- Average Exercise Price Per Share Beginning balance 4,828,723 $ 9.37 4,828,723 $ 9.37 4,828,723 $ 9.37 Warrants granted 15,128,151 $ 0.42 -- -- Warrants exercised (2,691,666 ) $ 0.01 Warrants expired/canceled -- -- -- Outstanding 17,265,208 $ 2.99 4,828,723 $ 9.37 4,828,723 $ 9.37 Exercisable 16,566,679 $ 2.78 4,130,194 $ 9.60 4,130,194 $ 9.60
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at January 1, 2018 1,156,027 $ 3.92 Granted 2,233,500 $ 0.40 Forfeited/cancelled (338,518 ) $ 3.10 Expired (27,370 ) $ 4.83 Exercised -- Outstanding at December 31, 2018 3,023,639 $ 1.40 9.3 -- Vested and Expected to Vest at December 31, 2018 1,893,518 $ 1.77 8.9 -- Exercisable at December 31, 2018 901,742 $ 2.79 8.1 --
Non Vested Stock Options Activity [Table Text Block]	<table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Non-vested Stock</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-Average Grant</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Date Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at January 1, 2018</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">835,708</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.37</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,233,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.32</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(651,180</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(296,131</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.35</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,121,897</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.64</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>" id="sjs-B6">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt">&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> &lt;tr style="vertical-align: bottom;"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;&lt;/td> &lt;td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Non-vested Stock&lt;/div> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;&lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;&lt;/td> &lt;td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-Average Grant&lt;/div> &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Date Fair Value&lt;/div> &lt;/td> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at January 1, 2018&lt;/div> &lt;/td> &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">835,708&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.37&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,233,500&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.32&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(651,180&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.97&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(296,131&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.35&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;&lt;/td> &lt;/tr> &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> &lt;td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> &lt;div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2018&lt;/div> &lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;&lt;/td> &lt;td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,121,897&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&lt;/td> &lt;td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;&lt;/td> &lt;td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.64&lt;/div>&lt;/td> &lt;td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;&lt;/td> &lt;/tr> &lt;/table>&lt;/div>
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 Expected life (years) 6 6 4 Risk-free interest rate 2.7% 2.3% 1.3% Expected volatility 103% 95% 102% Dividend yield 0% 0% 0%
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Year Ended December 31, Six Month Ended December 31, Year Ended June 30, 2018 2017 2017 Number of Shares Weighted -Average Grant Date Fair Value Number of Shares Weighted -Average Grant Date Fair Value Number of Shares Weighted -Average Grant Date Fair Value Balance at beginning of period 416 $17.60 59,694 $4.62 63,566 $14.96 Granted -- 10,000 $3.26 123,417 $4.55 Vested (416 ) $17.60 (69,278 ) $4.35 (125,513 ) $9.47 Forfeited -- -- (1,776 ) $27.05 Outstanding at end of period -- 416 $17.60 59,694 $4.62

Note 11 - Concentrations (Table

Note 11 - Concentrations (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 AXP $ 4,393,000 $ 2,475,000 $ 8,715,000 BioArchive 3,098,000 2,642,000 3,318,000 Manual Disposables 976,000 476,000 1,195,000 CAR-TXpress 907,000 151,000 Bone Marrow 135,000 180,000 745,000 Other 163,000 89,000 552,000 $ 9,672,000 $ 6,013,000 $ 14,525,000
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 2018 United States $ 4,854,000 $ 1,970,000 $ 6,675,000 Asia – other 1,717,000 983,000 1,951,000 Europe 1,165,000 721,000 1,739,000 China 1,143,000 2,176,000 3,296,000 Other 793,000 163,000 864,000 $ 9,672,000 $ 6,013,000 $ 14,525,000
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	December 31, December 31, 2018 2017 United States $ 1,614,000 $ 2,265,000 Costa Rica 601,000 276,000 India 211,000 288,000 All other countries 136,000 167,000 Total equipment, net $ 2,562,000 $ 2,996,000

Note 12 - Segment Reporting (Ta

Note 12 - Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Year Ended December 31, 2018 Clinical Development Device Total Net revenues $ 202,000 $ 9,470,000 $ 9,672,000 Cost of revenues 274,000 7,205,000 7,479,000 Gross profit (72,000 ) 2,265,000 2,193,000 Operating expenses 37,340,000 8,398,000 45,738,000 Operating loss $ (37,412,000 ) $ (6,133,000 ) $ (43,545,000 ) Depreciation and amortization $ 272,000 $ 398,000 $ 670,000 Stock-based compensation expense $ 473,000 $ 179,000 $ 652,000 Goodwill -- $ 781,000 $ 781,000 Total assets $ 3,796,000 $ 10,815,000 $ 14,611,000 Six Months Ended December 31, 2017 Clinical Development Device Total Net revenues $ 186,000 $ 5,827,000 $ 6,013,000 Cost of revenues 205,000 3,653,000 3,858,000 Gross profit (19,000 ) 2,174,000 2,155,000 Operating expenses 2,138,000 4,615,000 6,753,000 Operating loss $ (2,157,000 ) $ (2,441,000 ) $ (4,598,000 ) Depreciation and amortization $ 152,000 $ 170,000 $ 322,000 Stock-based compensation expense $ 164,000 $ 127,000 $ 291,000 Goodwill $ 13,195,000 $ 781,000 $ 13,976,000 Total assets $ 41,261,000 $ 9,850,000 $ 51,111,000 Year Ended June 30, 2017 Clinical Development Device Total Net revenues $ 492,000 $ 14,033,000 $ 14,525,000 Cost of revenues 466,000 8,220,000 8,686,000 Gross profit 26,000 5,813,000 5,839,000 Operating expenses 9,095,000 6,113,000 15,208,000 Operating loss $ (9,069,000 ) $ (300,000 ) $ (9,369,000 ) Depreciation and amortization $ 501,000 $ 329,000 $ 830,000 Stock-based compensation expense $ 970,000 $ 491,000 $ 1,461,000

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, Six Months Ended December 31, Year Ended June 30, 2018 2017 2017 Statutory federal income tax benefit $ (9,591,000 ) $ (1,703,000 ) $ (10,121,000 ) Intangible assets 3,119,000 -- -- Change in valuation allowance (2,084,000 ) -- -- Expiration of net operating losses 1,271,000 (14,427,000 ) 2,281,000 United States tax reform rate change -- 13,658,000 -- Disallowed financing costs 240,000 149,000 6,959,000 State and local taxes 2,344,000 60,000 88,000 Other (29,000 ) 25,000 120,000 Total income tax benefit $ (4,730,000 ) $ (2,238,000 ) $ (673,000 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 27,312,000 $ 29,682,000 Income tax credit carryforwards 2,769,000 2,667,000 Stock compensation 850,000 751,000 Other 1,027,000 831,000 Total deferred tax assets 31,958,000 33,931,000 Deferred tax liabilities Indefinite lived intangible assets -- (4,730,000 ) Depreciation and amortization (419,000 ) (126,000 ) Total deferred tax liabilities (419,000 ) (4,856,000 ) Valuation allowance (31,539,000 ) (33,805,000 ) Net deferred taxes $ -- $ (4,730,000 )

Note 15 - Prior Period Financ_2

Note 15 - Prior Period Financial Statement Revision (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	For the Six Months Ended December 31, 2017 Statement of Comprehensive Loss Amounts Previously Reported Adjustment As Revised Net loss $ (2,283,000 ) $ (487,000 ) $ (2,770,000 ) Other comprehensive loss: Foreign currency translation adjustments (5,000 ) -- (5,000 ) Comprehensive loss (2,288,000 ) (487,000 ) (2,775,000 ) Comprehensive loss attributable to non-controlling interests (487,000 ) -- (487,000 ) Comprehensive loss attributable to common stockholders $ (1,801,000 ) $ (487,000 ) $ (2,288,000 )

Note 1 - Description of Busin_2

Note 1 - Description of Business, Going Concern and Basis of Presentation (Details Textual) - USD ($)	Aug. 28, 2018	May 18, 2018	Mar. 28, 2018	Dec. 01, 2017	Aug. 03, 2016	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017	Jul. 07, 2017
Stock Issued During Period, Shares, New Issues			609,636	898,402	600,000
Common Stock, Par or Stated Value Per Share							$ 0.001	$ 0.001
Shares Issued, Price Per Share			$ 2.27	$ 3	$ 4.10
Class of Warrant or Right, Issued During Period								15,128,151
Payments of Stock Issuance Costs		$ 680,000	$ 171,000	$ 327,000	$ 369,000
Units Issued, Price per Unit		$ 0.60
Proceeds from Issuance or Sale of Equity, Total		$ 5,500,000
Proceeds from Issuance or Sale of Equity, Net		$ 4,820,000
Proceeds from Issuance of Common Stock, Net			$ 1,213,000	$ 2,368,000	$ 2,092,000		$ 2,368,000	$ 6,629,000	$ 2,092,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance							3,513,000	2,400,000
Working Capital								2,261,000
Retained Earnings (Accumulated Deficit), Ending Balance							$ (187,640,000)	$ (227,435,000)
ThermoGenesis [Member]
Noncontrolling Interest, Ownership Percentage by Parent								80.00%
SynGen [Member]
Percentage Of Common Stock Issued To Acquiree Shareholders								20.00%		20.00%
Common Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.60
Warrants and Rights Outstanding, Term		5 years
Warrants Issused in Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.68
Warrants and Rights Outstanding, Term			5 years 182 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			304,818
Units [Member]
Number of Units Issued		6,475,001
Convertible Units, Number of Common Shares Called by Each Unit		1
Convertible Units, Number of Common Warrants Called by Each Unit		1
Units [Member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Pre-funded Units [member]
Number of Units Issued		2,691,666
Convertible Units, Number of Common Warrants Called by Each Unit		1
Convertible Units, Number of Pre-funded Warrants Called by Each Unit		1
Number of Units Exercised						2,691,666
Pre-funded Units [member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Pre-funded Units [member] | Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	1,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001
Shares Issued, Price Per Share	$ 0.18
Class of Warrant or Right, Issued During Period	2,965,000
Warrants Issued, Price Per Warrant	$ 0.17
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Proceeds from Issuance of Private Placement	$ 684,000
Proceeds from Issuance of Private Placement, Net	623,000
Payments of Stock Issuance Costs	$ 61,000
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit, Total								$ 7,200,000
Line of Credit Facility, Maximum Borrowing Capacity								$ 10,000,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	6 Months Ended	12 Months Ended
	Dec. 31, 2017USD ($)shares	Dec. 31, 2018USD ($)shares	Jun. 30, 2017USD ($)shares	Jan. 01, 2018USD ($)
Maximum Period Of Agreement		21 years
Contract with Customer, Liability, Revenue Recognized		$ 384,000
Contract with Customer, Liability, Current	$ 384,000	485,000
Contract with Customer, Liability, Noncurrent	331,000	303,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance	3,513,000	2,400,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total	$ (5,000)	$ 30,000	$ (1,000)
Number of Reportable Segments		2
Income Tax Examination, Penalties and Interest Accrued, Total		$ 0
Unrecognized Tax Benefits, Ending Balance		$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	5,985,166	68,694,403	5,285,805
Retained Earnings [Member]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Retained Earnings [Member] | Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ (79,000)
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		2,965,000
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life		3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life		10 years
INDIA
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 71,000	$ 11,000
Cord Blood Storage Revenue [Member]
Contract with Customer, Liability, Revenue Recognized		$ 257,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Net revenues	$ 6,013,000	$ 9,672,000	$ 14,525,000
Device [Member]
Net revenues		9,469,000
Device [Member] | AXP [Member]
Net revenues		4,393,000
Device [Member] | BioArchive [Member]
Net revenues		3,098,000
Device [Member] | Manual Disposables [Member]
Net revenues		976,000
Device [Member] | CAR-TXpress [Member]
Net revenues		907,000
Device [Member] | Other Subsegments [Member]
Net revenues		95,000
Clinical Development [Member]
Net revenues		203,000
Clinical Development [Member] | Other Subsegments [Member]
Net revenues		68,000
Clinical Development [Member] | Bone Marrow [Member]
Net revenues		135,000
Device Revenue [Member]
Net revenues		7,844,000
Device Revenue [Member] | Device [Member]
Net revenues		7,806,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues		4,131,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues		1,792,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues		976,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues		907,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Device Revenue [Member] | Clinical Development [Member]
Net revenues		38,000
Device Revenue [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues		38,000
Device Revenue [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues
Service [Member]
Net revenues		1,733,000
Service [Member] | Device [Member]
Net revenues		1,568,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues		262,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues		1,306,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Service [Member] | Clinical Development [Member]
Net revenues		165,000
Service [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues		30,000
Service [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues		135,000
Other [Member]
Net revenues		95,000
Other [Member] | Device [Member]
Net revenues		95,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues		95,000
Other [Member] | Clinical Development [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Dec. 31, 2018USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 1,768,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	1,516,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 252,000

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Dec. 31, 2018USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 1,768,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,049,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 383,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 126,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 210,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,516,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,035,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 369,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 112,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 252,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 14,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 210,000

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares		6 Months Ended	12 Months Ended
		Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Anti-dilutive securities (in shares)		5,985,166	68,694,403	5,285,805
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)			48,405,556
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		404,412	404,412	404,412
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	698,529	698,529	698,529
Warrant, Other [Member]
Anti-dilutive securities (in shares)		3,725,782	16,162,267	3,725,782
Employee Stock Option [Member]
Anti-dilutive securities (in shares)		1,156,027	3,023,639	397,388
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)		416		59,694
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Acquisition of SynGe_2

Note 3 - Acquisition of SynGen (Details Textual) - USD ($)	Jul. 07, 2017	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Payments to Acquire Businesses, Gross		$ 1,000,000
SynGen [Member]
Payments to Acquire Businesses, Gross	$ 1,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,000,000
Percentage Of Common Stock Issued To Acquiree Shareholders	20.00%			20.00%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,528,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 107,000	$ 907,000
SynGen [Member] | General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs		$ 208,000

Note 3 - Acquisition of SynGe_3

Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) - USD ($)	Jul. 07, 2017	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Cash		$ 1,000,000
Goodwill		$ 13,976,000	$ 781,000
SynGen [Member]
Cash	$ 1,000,000
2,000,000 common shares of ThermoGenesis	2,528,000
Inventories	649,000
Finite-lived intangible assets	1,528,000
Equipment	585,000
Total assets	2,762,000
Other liabilities	15,000
Net assets acquired	(2,747,000)
Goodwill	781,000
SynGen [Member] | Developed Technology Rights [Member]
Finite-lived intangible assets	318,000
SynGen [Member] | Trade Names [Member]
Finite-lived intangible assets	26,000
SynGen [Member] | In Process Research and Development [Member]
Finite-lived intangible assets	1,143,000
SynGen [Member] | Customer Relationships [Member]
Finite-lived intangible assets	$ 41,000

Note 3 - Acquisition of SynGe_4

Note 3 - Acquisition of SynGen - Preliminary Allocation of Consideration Transferred to Net Assets Acquired (Details) (Parentheticals)	Jul. 07, 2017shares
SynGen [Member]
Common shares issued (in shares)	2,000,000

Note 3 - Acquisition of SynGe_5

Note 3 - Acquisition of SynGen Inc.- Supplemental Pro Forma Data (Details) - SynGen [Member] - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2017
Net revenues	$ 6,013,000	$ 15,592,000
Net loss	$ (2,600,000)	$ (30,701,000)
Basic and diluted net loss per common share (in dollars per share)	$ (0.21)	$ (3.39)

Note 4 - Intangible Assets an_3

Note 4 - Intangible Assets and Goodwill (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Goodwill, Impairment Loss		$ 13,195,000
Impairment of Intangible Assets (Excluding Goodwill), Total		19,886,000
Amortization of Intangible Assets, Total	$ 68,000	$ 131,000	$ 359,000
Noncompete Agreements [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total			$ 310,000

Note 4 - Intangible Assets an_4

Note 4 - Intangible Assets and Goodwill - Goodwill and Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
Intangible assets at December 31, 2017, net	$ 21,629,000
Goodwill at December 31, 2017, net	13,976,000
Intangible assets, amortization and foreign exchange (current year)	(152,000)
Goodwill, foreign exchange (current year)
Intangible assets, impairment loss	(19,886,000)
Goodwill, impairment loss	(13,195,000)
Intangible assets at September 30, 2018, net	1,591,000
Goodwill at September 30, 2018, net	$ 781,000

Note 4 - Intangible Assets an_5

Note 4 - Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Gross Carrying Amount	$ 1,355,000	$ 1,445,000
Accumulated Amortization	891,000	829,000
Net	448,000	616,000
Impairment	16,000
Gross Carrying Amount	22,368,000	22,458,000
Impairment of Intangible Assets (Excluding Goodwill), Total	19,886,000
Net	1,591,000	21,629,000
In Process Techonology [Member]
Gross Carrying Amount	1,143,000	1,143,000
Impairment
Net	1,143,000
Clinical Protocols [Member]
Gross Carrying Amount	19,870,000	$ 19,870,000
Impairment	19,870,000
Net
Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life	3 years	7 years
Gross Carrying Amount	$ 54,000	$ 56,000
Accumulated Amortization	38,000	21,000
Net	$ 16,000	$ 35,000
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life	10 years	10 years
Gross Carrying Amount	$ 318,000	$ 318,000
Accumulated Amortization	48,000	16,000
Net	$ 270,000	$ 302,000
Licensing Agreements [Member]
Finite-Lived Intangible Asset, Useful Life	7 years	7 years
Gross Carrying Amount	$ 448,000	$ 489,000
Accumulated Amortization	307,000	271,000
Net	$ 141,000	$ 218,000
Device Registration [Member]
Finite-Lived Intangible Asset, Useful Life	7 years	7 years
Gross Carrying Amount	$ 84,000	$ 92,000
Accumulated Amortization	68,000	65,000
Net		$ 27,000
Impairment	$ 16,000
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life	3 years	3 years
Gross Carrying Amount	$ 451,000	$ 490,000
Accumulated Amortization	430,000	456,000
Net	21,000	$ 34,000
Impairment

Note 4 - Intangible Assets an_6

Note 4 - Intangible Assets and Goodwill - Future Amortization Expense (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
2019	$ 122,000
2020	111,000
2021	40,000
2022	32,000
2023	32,000
Thereafter	111,000
Total	$ 448,000	$ 616,000

Note 5 - Equipment, Net (Detail

Note 5 - Equipment, Net (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Depreciation, Total	$ 254,000	$ 539,000	$ 408,000

Note 5 - Equipment, Net - Summa

Note 5 - Equipment, Net - Summary of Property, Plant, and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant, and Equipment, Gross	$ 7,995,000	$ 8,006,000
Less accumulated depreciation and amortization	(5,433,000)	(5,010,000)
Total equipment and leasehold improvements, net	2,562,000	2,996,000
Machinery and Equipment [Member]
Property, Plant, and Equipment, Gross	$ 6,136,000	6,507,000
Machinery and Equipment [Member] | Minimum [Member]
Estimated Useful Life (Year)	2 years 182 days
Machinery and Equipment [Member] | Maximum [Member]
Estimated Useful Life (Year)	10 years
Computer and Software [Member]
Property, Plant, and Equipment, Gross	$ 664,000	718,000
Computer and Software [Member] | Minimum [Member]
Estimated Useful Life (Year)	2 years
Computer and Software [Member] | Maximum [Member]
Estimated Useful Life (Year)	5 years
Office Equipment [Member]
Property, Plant, and Equipment, Gross	$ 264,000	253,000
Office Equipment [Member] | Minimum [Member]
Estimated Useful Life (Year)	5 years
Office Equipment [Member] | Maximum [Member]
Estimated Useful Life (Year)	10 years
Leasehold Improvements [Member]
Property, Plant, and Equipment, Gross	$ 931,000	$ 528,000
Leasehold Improvements, Estimated Useful Life	Shorter of 5 years or remaining lease term

Note 6 - Related Party Transa_2

Note 6 - Related Party Transactions (Details Textual) - USD ($)	Mar. 12, 2018	Aug. 21, 2017	Mar. 06, 2017	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2017	Aug. 28, 2018	May 18, 2018	Apr. 16, 2018	Apr. 01, 2018
Units Issued, Price per Unit										$ 0.60
Amortization of Debt Discount (Premium)						$ 1,174,000		$ 9,851,000
Interest Expense, Total					541,000	2,697,000		20,519,000
Revenue from Related Parties					1,679,000	669,000		308,000
Adjustments for New Accounting Principle, Early Adoption [Member] | Accounting Standards Update 2017-11 [Member]
Debt Instrument, Unamortized Discount, Total												$ 7,200,000
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price									$ 0.18	$ 0.60	$ 1.61
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity						10,000,000
Proceeds from Long-term Lines of Credit						7,200,000	$ 6,700,000
Line of Credit Facility, Remaining Borrowing Capacity						2,800,000
Debt Instrument, Interest Rate, Stated Percentage			22.00%
Debt Instrument, Convertible, Percentage of Conversion Price			90.00%
Debt Instrument, Number of Trading Days Prior to the Maturity Date			10 days
Interest Payable					657,000	1,513,000	657,000				$ 657,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total				$ 657,000
Interest Expense, Total					535,000	1,513,000		122,000
Boyalife W.S.N. [Member]
Distributor Agreement Term		3 years
Distributor Agreement, Renewal Term		2 years
Revenue from Related Parties					1,679,000	665,000		$ 308,000
Accounts Receivable, Related Parties					$ 862,000	$ 0	862,000
IncoCell [Member]
Revenue from Related Parties	$ 14,000
Accounts Receivable, Related Parties	$ 14,000
Contract Development Revenue, Term	10 years
Boyalife Group Ltd. [Member] | Legal Expenses Reimbursement [Member]
Related Party Transaction, Amounts of Transaction							$ 606,000

Note 7 - Convertible Debentur_2

Note 7 - Convertible Debentures (Details Textual) - USD ($)	Mar. 28, 2018	Dec. 01, 2017	Aug. 22, 2016	Aug. 03, 2016	Feb. 29, 2016	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Stock Issued During Period, Shares, New Issues	609,636	898,402		600,000
Stock Issued During Period, Value, New Issues						$ 2,368,000	$ 6,629,000	$ 2,092,000
Amortization of Debt Discount (Premium)							1,174,000	9,851,000
Amortization of Debt Issuance Costs								$ 160,000
Warrants Issued in Connection with Convertible Debentures [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					3,529,412
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 8
Warrant Expiration Period					5 years
Number of Warrants, Percentage of Shares Issued or to Be Issued					80.00%
Common Stock [Member]
Stock Issued During Period, Shares, New Issues						898,402	8,084,637	600,000
Stock Issued During Period, Value, New Issues						$ 1,000	$ 8,000	$ 1,000
Convertible Debt [Member] | Boyalife Investment Inc. [Member]
Debt Conversion, Original Debt Principal, Amount			$ 12,500,000
Debt Conversion, Original Debt Interest, Amount			8,250,000
Additional Interest Expense, Debt			3,153,000
Amortization of Debt Discount (Premium)			9,538,000
Amortization of Debt Issuance Costs			$ 155,000
Convertible Debt [Member] | Boyalife Investment Inc. [Member] | Common Stock [Member]
Debt Conversion, Convertible Shares					3,676,471
Debt Conversion, Converted Instrument, Shares Issued			6,102,941
Convertible Debt [Member] | Boyalife Investment Inc. [Member] | Common Stock [Member] | Conversion of Interest [Member]
Debt Conversion, Converted Instrument, Shares Issued			2,426,470
Debt Conversion, Converted Instrument, Amount			$ 11,403,000
Boyalife Investment Inc. [Member]
Gross Proceeds from Financing Transaction					$ 15,000,000
Stock Issued During Period, Shares, New Issues					735,294
Sale of Stock, Price Per Share					$ 3.40
Stock Issued During Period, Value, New Issues					$ 2,500,000
Debt Instrument, Face Amount					$ 12,500,000

Note 8 - Derivative Obligatio_3

Note 8 - Derivative Obligations (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017	Jun. 30, 2016
Class of Warrant or Right, Outstanding	4,828,723	17,265,208	4,828,723	4,828,723
Derivative, Gain (Loss) on Derivative, Net, Total	$ 133,000	$ 596,000	$ (60,000)
Series A Warrant [Member]
Class of Warrant or Right, Outstanding				404,412

Note 8 - Derivative Obligatio_4

Note 8 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member]	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2017
Measurement Input, Share Price [Member]
Valuation assumption	0.27	3	3.17
Measurement Input, Price Volatility [Member]
Valuation assumption	0.94	1.07	1.1
Measurement Input, Expected Term [Member]
Valuation assumption	2.2	3.2	3.7
Measurement Input, Discount Rate [Member]
Valuation assumption	0.0248	0.0199	0.0166
Measurement Input, Expected Dividend Rate [Member]
Valuation assumption	0	0	0
Measurement Input, Exercise Price [Member]
Valuation assumption	8	8	8

Note 8 - Derivative Obligatio_5

Note 8 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2017
Derivative obligations	$ 1,000	$ 597,000	$ 730,000
Fair Value, Inputs, Level 1 [Member]
Derivative obligations
Fair Value, Inputs, Level 2 [Member]
Derivative obligations
Fair Value, Inputs, Level 3 [Member]
Derivative obligations	$ 1,000	$ 597,000

Note 8 - Derivative Obligatio_6

Note 8 - Derivative Obligations - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Balance	$ 730,000	$ 597,000
Change in fair value of derivative obligation	(133,000)	(596,000)	$ 60,000
Change in fair value of derivative obligation	(133,000)	(596,000)	60,000
Balance	$ 597,000	$ 1,000	$ 730,000

Note 9 - Commitments and Cont_3

Note 9 - Commitments and Contingencies (Details Textual) - USD ($)	May 04, 2017	Oct. 31, 2017	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017	Jan. 31, 2019
Operating Leases, Rent Expense, Net, Total			$ 241,000	$ 517,000	$ 291,000
Payment Terms, Severance Compensation				1 year
Short Term Investment Minimum				$ 2,000,000
Minimum [Member]
Period Of Warranty On Products				1 year
Maximum [Member]
Period Of Warranty On Products				2 years
Potential Severance Cost for Chief Operating Officer [Member]
Loss Contingency, Estimate of Possible Loss				$ 2,300,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value	$ 1,000,000
Loss Contingency, Negotiation Condition Bond		$ 1,000,000
Loss Contingency Accrual, Ending Balance				$ 0
Subsequent Event [Member]
Lessee, Operating Lease, Renewal Term						5 years

Note 9 - Commitments and Cont_4

Note 9 - Commitments and Contingencies - Future Minimum Lease Payments for Non-cancelable Operating Lease (Details)	Dec. 31, 2018USD ($)
2019	$ 311,000
2020	301,000
2021	310,000
2022	319,000
2023	329,000
Thereafter	139,000
Total	$ 1,709,000

Note 9 - Commitments and Cont_5

Note 9 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Beginning balance	$ 588,000	$ 291,000	$ 566,000
Warranties issued during the period	95,000	199,000	120,000
Settlements made during the period	(359,000)	(252,000)	(93,000)
Changes in liability for pre-existing warranties during the period	(33,000)	(52,000)	(5,000)
Ending balance	$ 291,000	$ 186,000	$ 588,000

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual) - USD ($)	Dec. 14, 2018	Aug. 28, 2018	May 18, 2018	Mar. 28, 2018	Dec. 29, 2017	Dec. 01, 2017	Jul. 01, 2017	Aug. 22, 2016	Aug. 03, 2016	Jul. 26, 2016	Jul. 07, 2016	Jun. 30, 2018	Jul. 31, 2016	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017	Jun. 22, 2018	May 05, 2017
Stock Issued During Period, Shares, New Issues				609,636		898,402			600,000
Shares Issued, Price Per Share				$ 2.27		$ 3			$ 4.10
Class of Warrant or Right, Issued During Period																	15,128,151
Payments of Stock Issuance Costs			$ 680,000	$ 171,000		$ 327,000			$ 369,000
Units Issued, Price per Unit			$ 0.60
Proceeds from Issuance or Sale of Equity, Total			$ 5,500,000
Proceeds from Issuance or Sale of Equity, Net			$ 4,820,000
Proceeds from Issuance of Common Stock, Net				$ 1,213,000		2,368,000			$ 2,092,000							$ 2,368,000	$ 6,629,000	$ 2,092,000
Proceeds from Issuance of Common Stock						$ 2,700,000
Allocated Share-based Compensation Expense, Total																$ 291,000	$ 652,000	$ 1,461,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance																1,156,027	3,023,639
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																	2,233,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																	$ 0.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value																$ 8,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value																$ 2.36	$ 0.32	$ 2.16
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost														$ 94,000	$ 539,000
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,140,000				300,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.2979				$ 3
Share-based Compensation Arrangements by Share-based Payment Award, Options, Subject to Approval of Amendment Plan	1,699,333
Principal Financial and Accounting Officer [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.2979
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options																	$ 1,202,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value																$ 209,000	$ 633,000	$ 572,000
Employee Stock Option [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years				5 years
Employee Stock Option [Member] | Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number														16,248	72,496
Employee Stock Option [Member] | Principal Financial and Accounting Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Restricted Stock Units (RSUs) [Member]
Shares Paid for Tax Withholding for Share Based Compensation																16,456		145
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																69,278	416	125,513
Restricted Stock Units (RSUs) [Member] | Former Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number														15,914	79,720
Share-based Compensation Arrangement by Share-based Payment Award, Pre-Modification of Agreement																90 years
Short Term Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period										98,417			118,288
Shares Paid for Tax Withholding for Share Based Compensation													46,879
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized											104,000
Share-based Compensation Arrangement by Share-based Payment Award, Aggregate Amount of Issuable Cash Award											$ 276,000
Share-based Compensation Arrangement by Share-based Payment Award, Amount of Cash Award Issued in Period										$ 266,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period							46,781			51,636
Amended 2016 Plan [Member
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,950,000																		1,325,000	600,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																	901,100
Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																	25,000
Common Stock, Capital Shares Reserved for Future Issuance																	2,444
Plan 2012 [Member] | Employee Stock Option [Member]
Options Prices In Terms Of Fair Market Value																	100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																	1 year
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance																	62,676
Equity Incentive Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					1,000,000
Common Stock, Capital Shares Reserved for Future Issuance																	775,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					280,000
The 2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											156,100
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 2.86
The 2016 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period											7 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period											3 years
Convertible Debt [Member] | Boyalife Investment Inc. [Member]
Debt Conversion, Original Debt Principal, Amount								$ 12,500,000
Debt Conversion, Original Debt Interest, Amount								$ 8,250,000
Common Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.60
Warrants and Rights Outstanding, Term			5 years
Warrants Issused in Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.68
Warrants and Rights Outstanding, Term				5 years 182 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				304,818
Units [Member]
Number of Units Issued			6,475,001
Convertible Units, Number of Common Shares Called by Each Unit			1
Convertible Units, Number of Common Warrants Called by Each Unit			1
Units [Member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Pre-funded Units [member]
Number of Units Issued			2,691,666
Convertible Units, Number of Common Warrants Called by Each Unit			1
Convertible Units, Number of Pre-funded Warrants Called by Each Unit			1
Number of Units Exercised												2,691,666
Pre-funded Units [member] | Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Pre-funded Units [member] | Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Common Stock [Member]
Stock Issued During Period, Shares, New Issues																898,402	8,084,637	600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																5,333
Common Stock [Member] | Convertible Debt [Member] | Boyalife Investment Inc. [Member]
Debt Conversion, Converted Instrument, Shares Issued								6,102,941
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		1,000,000
Shares Issued, Price Per Share		$ 0.18
Class of Warrant or Right, Issued During Period		2,965,000
Warrants Issued, Price Per Warrant		$ 0.17
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Proceeds from Issuance of Private Placement		$ 684,000
Proceeds from Issuance of Private Placement, Net		623,000
Payments of Stock Issuance Costs		$ 61,000

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Warrant Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Outstanding (in shares)	4,828,723	4,828,723	4,828,723
Outstanding, weighted average exercise price (in dollars per share)	$ 9.37	$ 9.37	$ 9.37
Warrants granted (in shares)		15,128,151
Warrants granted, weighted average exercise price (in dollars per share)		$ 0.42
Warrants exercised (in shares)		(2,691,666)
Warrants exercised, weighted average exercise price (in dollars per share)		$ 0.01
Warrants expired/canceled (in shares)
Warrants expired/canceled, weighted average exercise price (in dollars per share)
Outstanding (in shares)	4,828,723	17,265,208	4,828,723
Outstanding, weighted average exercise price (in dollars per share)	$ 9.37	$ 2.99	$ 9.37
Exercisable (in shares)	4,130,194	16,566,679	4,130,194
Exercisable, weighted average exercise price (in dollars per share)	$ 9.60	$ 2.78	$ 9.60

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	1,156,027
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.92
Granted, options (in shares) | shares	2,233,500
Granted, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.40
Forfeited/cancelled (in shares) | shares	(338,518)
Forfeited/cancelled, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.10
Expired, options (in shares) | shares	(27,370)
Expired, weighted average exercise price, options (in dollars per share) | $ / shares	$ 4.83
Outstanding, options (in shares) | shares	3,023,639
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 1.40
Outstanding, weighted average remaining contractual life, options (Year)	9 years 109 days
Outstanding, aggregate intrinsic value, options | $
Vested and Expected to Vest, options (in shares) | shares	1,893,518
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 1.77
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	8 years 328 days
Vested and Expected to Vest, aggregate intrinsic value, options | $
Exercisable, options (in shares) | shares	901,742
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 2.79
Exercisable, weighted average remaining contractual life, options (Year)	8 years 36 days
Exercisable, aggregate intrinsic value, options | $

Note 10 - Stockholders' Equit_5

Note 10 - Stockholders' Equity - Non-vested Stock Options Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Outstanding, options (in shares)		1,156,027
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,233,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 2.36	$ 0.32	$ 2.16
Forfeited (in shares)		(338,518)
Outstanding, options (in shares)	1,156,027	3,023,639
Non-vested Stock Options [Member]
Outstanding, options (in shares)		835,708
Outstanding at January 1, 2018 (in dollars per share)		$ 2.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,233,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.32
Vested (in shares)		(651,180)
Vested (in dollars per share)		$ 0.97
Forfeited (in shares)		(296,131)
Forfeited (in dollars per share)		$ 2.35
Outstanding, options (in shares)	835,708	2,121,897
Outstanding at December 31, 2018 (in dollars per share)	$ 2.37	$ 0.64

Note 10 - Stockholders' Equit_6

Note 10 - Stockholders' Equity - Schedule of Assumptions (Details)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Expected life (years) (Year)	6 years	6 years	4 years
Risk-free interest rate	2.30%	2.70%	1.30%
Expected volatility	95.00%	103.00%	102.00%
Dividend yield	0.00%	0.00%	0.00%

Note 10 - Stockholders' Equit_7

Note 10 - Stockholders' Equity - Restricted Stock Unit Activity Granted to Employees (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Balance at beginning of period (in shares)	59,694	416	63,566
Balance at beginning of period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 4.62	$ 17.60	$ 14.96
Granted, Number of Shares (in shares)	10,000		123,417
Granted, Weighted Average Grant Date Fair Value (in dollars per share)	$ 3.26		$ 4.55
Vested, Number of Shares (in shares)	(69,278)	(416)	(125,513)
Vested, Weighted Average Grant Date Fair Value (in dollars per share)	$ 4.35	$ 17.60	$ 9.47
Forfeited, Number of Shares (in shares)			(1,776)
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)			$ 27.05
Outstanding at end of period (in shares)	416		59,694
Outstanding at end of period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 17.60		$ 4.62

Note 11 - Concentrations (Detai

Note 11 - Concentrations (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2017
Accounts Receivable, Net, Current, Total	$ 1,687,000	$ 1,495,000	$ 1,687,000
Revenue from Contract with Customer, Including Assessed Tax	4,334,000	9,003,000		$ 14,217,000
Revenue from Related Parties	1,679,000	669,000		308,000
Related Distributor [Member]
Accounts Receivable, Net, Current, Total	862,000	0	$ 862,000
Revenue from Related Parties	$ 1,679,000	$ 664,000		$ 308,000
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Related Distributor [Member]
Concentration Risk, Percentage		34.00%	34.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Related Distributor [Member]
Concentration Risk, Percentage	28.00%	7.00%		2.00%
Supplier Concentration Risk [Member] | Cost of Goods, Total [Member] | Supplier 1 [Member]
Concentration Risk, Percentage	61.00%	43.00%		64.00%
Supplier Concentration Risk [Member] | Cost of Goods, Total [Member] | Supplier 2 [Member]
Concentration Risk, Percentage		14.00%		20.00%
Customer 1 [Member]
Accounts Receivable, Related Parties	$ 172,000	$ 494,000	$ 172,000
Revenue from Contract with Customer, Including Assessed Tax	$ 560,000	$ 2,120,000		$ 3,263,000
Customer 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage		33.00%	7.00%
Customer 1 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	9.00%	22.00%		22.00%
Distributor 1 [Member]
Accounts Receivable, Related Parties	$ 12,000	$ 229,000	$ 12,000
Revenue from Contract with Customer, Including Assessed Tax	$ 480,000	$ 461,000		$ 2,842,000
Distributor 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage		15.00%
Distributor 1 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	8.00%	5.00%		20.00%
Distributor 3 [Member]
Accounts Receivable, Related Parties		$ 220,000
Accounts Receivable, Net, Current, Total	$ 464,000		$ 464,000
Distributor 3 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	18.00%	15.00%
Distributor [Member]
Revenue from Related Parties	$ 520,000	$ 861,000		$ 1,048,000
Distributor [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	9.00%	9.00%		7.00%

Note 11 - Concentrations - Reve

Note 11 - Concentrations - Revenues by Product Platform (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Net revenues	$ 6,013,000	$ 9,672,000	$ 14,525,000
Product Concentration Risk [Member] | AXP [Member]
Net revenues	2,475,000	4,393,000	8,715,000
Product Concentration Risk [Member] | BioArchive [Member]
Net revenues	2,642,000	3,098,000	3,318,000
Product Concentration Risk [Member] | Manual Disposables [Member]
Net revenues	476,000	976,000	1,195,000
Product Concentration Risk [Member] | CAR-TXpress [Member]
Net revenues	151,000	907,000
Product Concentration Risk [Member] | Bone Marrow [Member]
Net revenues	180,000	135,000	745,000
Product Concentration Risk [Member] | Product and Service, Other [Member]
Net revenues	$ 89,000	$ 163,000	$ 552,000

Note 11 - Concentrations - Sale

Note 11 - Concentrations - Sales to Customers (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Net revenues	$ 6,013,000	$ 9,672,000	$ 14,525,000
Geographic Concentration Risk [Member] | UNITED STATES
Net revenues	1,970,000	4,854,000	6,675,000
Geographic Concentration Risk [Member] | Asia - Other [Member]
Net revenues	983,000	1,717,000	1,951,000
Geographic Concentration Risk [Member] | Europe [Member]
Net revenues	721,000	1,165,000	1,739,000
Geographic Concentration Risk [Member] | CHINA
Net revenues	2,176,000	1,143,000	3,296,000
Geographic Concentration Risk [Member] | All Other Countries [Member]
Net revenues	$ 163,000	$ 793,000	$ 864,000

Note 11 - Concentrations - Summ

Note 11 - Concentrations - Summary of Net Equipment by Geographic Area (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant, and Equipment Concentration	$ 2,562,000	$ 2,996,000
Geographic Concentration Risk [Member] | UNITED STATES
Property, Plant, and Equipment Concentration	1,614,000	2,265,000
Geographic Concentration Risk [Member] | COSTA RICA
Property, Plant, and Equipment Concentration	601,000	276,000
Geographic Concentration Risk [Member] | INDIA
Property, Plant, and Equipment Concentration	211,000	288,000
Geographic Concentration Risk [Member] | All Other Countries [Member]
Property, Plant, and Equipment Concentration	$ 136,000	$ 167,000

Note 12 - Segment Reporting (De

Note 12 - Segment Reporting (Details Textual)	12 Months Ended
	Dec. 31, 2018
Number of Reportable Segments	2

Note 12 - Segment Reporting - S

Note 12 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Net revenues	$ 6,013,000	$ 9,672,000	$ 14,525,000
Cost of revenues	3,858,000	7,479,000	8,686,000
Gross profit	2,155,000	2,193,000	5,839,000
Operating expenses	6,753,000	45,738,000	15,208,000
Operating loss	(4,598,000)	(43,545,000)	(9,369,000)
Depreciation and amortization	322,000	670,000	830,000
Stock-based compensation expense	291,000	652,000	1,461,000
Goodwill	13,976,000	781,000
Total assets	51,111,000	14,611,000
Operating loss	(4,598,000)	(43,545,000)	(9,369,000)
Clinical Development [Member]
Net revenues		203,000
Clinical Development [Member] | Operating Segments [Member]
Net revenues	186,000	202,000	492,000
Cost of revenues	205,000	274,000	466,000
Gross profit	(19,000)	(72,000)	26,000
Operating expenses	2,138,000	37,340,000	9,095,000
Operating loss	(2,157,000)	(37,412,000)	(9,069,000)
Depreciation and amortization	152,000	272,000	501,000
Stock-based compensation expense	164,000	473,000	970,000
Goodwill	13,195,000
Total assets	41,261,000	3,796,000
Operating loss	(2,157,000)	(37,412,000)	(9,069,000)
Device [Member]
Net revenues		9,469,000
Device [Member] | Operating Segments [Member]
Net revenues	5,827,000	9,470,000	14,033,000
Cost of revenues	3,653,000	7,205,000	8,220,000
Gross profit	2,174,000	2,265,000	5,813,000
Operating expenses	4,615,000	8,398,000	6,113,000
Operating loss	(2,441,000)	(6,133,000)	(300,000)
Depreciation and amortization	170,000	398,000	329,000
Stock-based compensation expense	127,000	179,000	491,000
Goodwill	781,000	781,000
Total assets	9,850,000	10,815,000
Operating loss	$ (2,441,000)	$ (6,133,000)	$ (300,000)

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (4,551,000)	$ (45,458,000)	$ (29,005,000)
Income (Loss) from Continuing Operations before Income Taxes, Foreign	(457,000)	(212,000)	(763,000)
Income Tax Expense (Benefit), Total	$ (2,238,000)	$ (4,730,000)	(673,000)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	21.00%
Effective Income Tax Rate Reconciliation, Increase (Decrease) in Federal Statutory Income Tax Rate, Percent	(14.00%)
Deferred Tax Assets, Increase (Decrease) From Remeasurement Due to Change in Enacted Rate	$ (13,658,000)
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	0
Deferred Income Tax Expense (Benefit), Total	(2,238,000)	$ (4,730,000)	(673,000)
Deferred Income Tax (Benefit) Due to Prior Years State Rate Changes			(559,000)	$ (157,000)	$ (402,000)
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (14,296,000)	(2,266,000)	$ 2,209,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total		125,578,000
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount		1,604,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total		37,520,000
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount		1,475,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total		$ 2,430,000

Note 13 - Income Taxes - Reconc

Note 13 - Income Taxes - Reconciliation of Federal Income Tax Attributable to Operations to Income Tax Expense (Benefit) (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Statutory federal income tax benefit	$ (1,703,000)	$ (9,591,000)	$ (10,121,000)
Intangible assets		3,119,000
Change in valuation allowance		(2,084,000)
Expiration of net operating losses	(14,427,000)	1,271,000	2,281,000
United States tax reform rate change	13,658,000
Disallowed financing costs	149,000	240,000	6,959,000
State and local taxes	60,000	2,344,000	88,000
Other	25,000	(29,000)	120,000
Total income tax benefit	$ (2,238,000)	$ (4,730,000)	$ (673,000)

Note 13 - Income Taxes - Compon

Note 13 - Income Taxes - Components of Company's Deferred Tax Assets and Liabilities for Federal and State Income Taxes (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 27,312,000	$ 29,682,000
Income tax credit carryforwards	2,769,000	2,667,000
Stock compensation	850,000	751,000
Other	1,027,000	831,000
Total deferred tax assets	31,958,000	33,931,000
Deferred tax liabilities
Indefinite lived intangible assets		(4,730,000)
Depreciation and amortization	(419,000)	(126,000)
Total deferred tax liabilities	(419,000)	(4,856,000)
Valuation allowance	(31,539,000)	(33,805,000)
Net deferred taxes		$ (4,730,000)

Note 14 - Employee Retirement_2

Note 14 - Employee Retirement Plan (Details Textual) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 0	$ 0	$ 0

Note 15 - Prior Period Financ_3

Note 15 - Prior Period Financial Statement Revision - Effect of the Correction of the Immaterial Error on the Company's Statement of Comprehensive Loss (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 30, 2017
Net loss	$ (2,770,000)	$ (40,940,000)	$ (29,095,000)
Other comprehensive loss:
Foreign currency translation adjustments	(5,000)	30,000	(1,000)
Comprehensive loss	(2,775,000)	(40,910,000)	(29,096,000)
Comprehensive loss attributable to non-controlling interests	(487,000)	(1,224,000)
Comprehensive loss attributable to common stockholders	(2,288,000)	$ (39,686,000)	$ (29,096,000)
Previously Reported [Member]
Net loss	(2,283,000)
Other comprehensive loss:
Foreign currency translation adjustments	(5,000)
Comprehensive loss	(2,288,000)
Comprehensive loss attributable to non-controlling interests	(487,000)
Comprehensive loss attributable to common stockholders	(1,801,000)
Restatement Adjustment [Member]
Net loss	(487,000)
Other comprehensive loss:
Foreign currency translation adjustments
Comprehensive loss	(487,000)
Comprehensive loss attributable to non-controlling interests
Comprehensive loss attributable to common stockholders	$ (487,000)

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)	Jan. 29, 2019	Jan. 01, 2019	Dec. 31, 2018	Dec. 31, 2017
Common Stock, Par or Stated Value Per Share			$ 0.001	$ 0.001
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share	$ 0.001
Subsequent Event [Member] | Convertible Debt [Member] | Notes [Member]
Debt Instrument, Face Amount	$ 800,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%
Debt Instrument, Term	1 year 180 days
Debt Instrument, Convertible, First Customary Conversion Blockers	4.99%
Debt Instrument, Convertible, Second customary conversion blockers	9.99%
Subsequent Event [Member] | Convertible Debt [Member] | Notes [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.18
Subsequent Event [Member] | Convertible Debt [Member] | Notes [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.05
ThermoGenesis [Member]
Noncontrolling Interest, Ownership Percentage by Parent			80.00%
ThermoGenesis [Member] | Subsequent Event [Member]
Minority Interest Acquired Through Exchange		20.00%
Noncontrolling Interest, Ownership Percentage by Parent		100.00%
CAR-TXpress [Member] | Subsequent Event [Member]
Ownership in Subsidiary Exchanged		20.00%
Noncontrolling Interest, Ownership Percentage by Parent		80.00%